To address a potential contribution of phospholipase A2 (PLA2) or phospholipase D (PLD) in DAG generation for ASM activation, activity of the enzyme was assessed in lysates of HBMEC treated with PLA2 inhibitor AACOCF3 or PLD inhibitor 5-fluoro-2-indolyl des-chlorohalopemide (FIPI), respectively, prior to infection. The gene discussed is GPLD1; the disease is infection.